

Roche: Changes in the Board of Directors



Roche announced that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting (AGM) scheduled for 15 March 2022.

Mr Paul Bulcke, who has been serving on the Board of Directors since 2011, has decided not to stand for re-election at the AGM in 2022, following almost eleven years of tenure. The Board of Directors proposes Dr Jemilah Mahmood, currently the Executive Director of the Sunway Centre for Planetary Health in Malaysia, for election to the Board of Directors at the AGM 2022.

“As a member of the Board and of the Audit Committee, Paul Bulcke has made significant contributions to Roche’s success,” said Roche Chairman Christoph Franz. “On behalf of the Board of Directors, I would like to extend our sincere thanks to Paul Bulcke who gave great support to Roche with his enormous leadership experience and his strong entrepreneurial thinking.” Christoph Franz added: “I am delighted with our nomination of Jemilah Mahmood for election as a new member of the Board. Jemilah Mahmood brings a wealth of experience in public health and she has profound knowledge of the global challenges and opportunities for better healthcare for people, especially in less developed regions of the world. With this expertise, she can help make our medicines and diagnostics accessible to even more people worldwide.”

The following current members of the Board of Directors are recommended for re-election:

Name	Board member since
Dr Christoph Franz (as Chairman)	2011
André Hoffmann	1996
Julie Brown	2016
Professor Dr Hans Clevers	2019
Dr Jörg Duschmalé	2020
Dr Patrick Frost	2020
Anita Hauser	2017
Professor Dr Richard P. Lifton	2015
Bernard Poussot	2015
Dr Severin Schwan	2013
Dr Claudia Süssmuth Dyckerhoff	2016

Published on : Fri, 3 Dec 2021